- Home
- RCON vs GANX Comparison
RCON vs GANX Comparison
Compare RCON & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCON
- GANX
- Stock Information
- Founded
- RCON 2007
- GANX 2017
- Country
- RCON China
- GANX United States
- Employees
- RCON N/A
- GANX N/A
- Industry
- RCON Oilfield Services/Equipment
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- RCON Energy
- GANX Health Care
- Exchange
- RCON Nasdaq
- GANX Nasdaq
- Market Cap
- RCON 45.3M
- GANX 45.8M
- IPO Year
- RCON 2009
- GANX 2021
- Fundamental
- Price
- RCON $1.63
- GANX $1.90
- Analyst Decision
- RCON
- GANX Strong Buy
- Analyst Count
- RCON 0
- GANX 5
- Target Price
- RCON N/A
- GANX $8.20
- AVG Volume (30 Days)
- RCON 13.4K
- GANX 271.1K
- Earning Date
- RCON 01-01-0001
- GANX 05-13-2025
- Dividend Yield
- RCON N/A
- GANX N/A
- EPS Growth
- RCON N/A
- GANX N/A
- EPS
- RCON N/A
- GANX N/A
- Revenue
- RCON $8,996,572.00
- GANX N/A
- Revenue This Year
- RCON N/A
- GANX N/A
- Revenue Next Year
- RCON $12.17
- GANX N/A
- P/E Ratio
- RCON N/A
- GANX N/A
- Revenue Growth
- RCON N/A
- GANX N/A
- 52 Week Low
- RCON $1.32
- GANX $0.89
- 52 Week High
- RCON $3.70
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- RCON 47.36
- GANX 50.93
- Support Level
- RCON $1.45
- GANX $1.67
- Resistance Level
- RCON $1.97
- GANX $1.99
- Average True Range (ATR)
- RCON 0.13
- GANX 0.16
- MACD
- RCON -0.00
- GANX 0.03
- Stochastic Oscillator
- RCON 38.60
- GANX 81.69
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.